Castration-resistant Prostate Cancer and Intra-prostatic Hormonal Status
NCT ID: NCT03014973
Last Updated: 2018-09-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2017-01-31
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prostatic Cancer Versus Androgen Deficiency
NCT02235142
Measurements of Sexual Steroids' Concentrations in Prostatic Tissue
NCT04256161
Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients
NCT01313273
A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer
NCT02066961
Treatment Patterns Among Patients With Prostate Cancer Prior to Diagnosis of a Castration-resistant State
NCT01560858
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
prostate cancer patients resistant to castration
intra-prostatic concentration of sexual steroids
Trans-rectal biopsy
patients naif of hormonal treatment
intra-prostatic concentration of sexual steroids
Trans-rectal biopsy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
intra-prostatic concentration of sexual steroids
Trans-rectal biopsy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* group 2: Patients with a castration-resistant prostate cancer resisting defined by a biological progression
* group 2a: without radiotherapy
* group 2b: with radiotherapy
* Affiliated to a social security scheme
* Having given a written consent.
Exclusion Criteria
* neuro-endocrine form or sarcomatoid form prostate cancer
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hopital Foch
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yann NEUZILLET, MD
Role: PRINCIPAL_INVESTIGATOR
Hopital Foch
Henry Botto, MD
Role: STUDY_CHAIR
Hopital Foch
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hopital Foch
Suresnes, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-A00020-51
Identifier Type: OTHER
Identifier Source: secondary_id
2016/03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.